Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gastrointestinal stromal tumors (GIST) are driven by KIT/PDGFRA oncogenic signaling, presenting a target for molecularly targeted therapies.
• Drug development has successfully leveraged this vulnerability, leading to treatments like imatinib.
• Recent advancements include avapritinib and ripretinib, offering improved precision kinase inhibition for imatinib-resistant GIST and addressing tumor heterogeneity.

Purpose of the Study:

• To evaluate new molecularly targeted therapies for GIST.
• To identify mechanisms of drug response and resistance in GIST.
• To address clinical challenges in early-stage GIST eradication and late-stage disease response maximization.

Main Methods:

• Exploiting the reliance on KIT/PDGFRA oncogenic signaling for therapeutic vulnerability.
• Developing and evaluating novel precision kinase inhibitors (avapritinib, ripretinib).
• Investigating mechanisms of adaptation to KIT inhibition and apoptosis evasion.

Main Results:

• Avapritinib and ripretinib represent advancements in precision kinase inhibition for GIST.
• These therapies aim to address tumor heterogeneity in imatinib-resistant GIST.
• Understanding drug response and resistance mechanisms is crucial for further therapeutic development.

Conclusions:

• Future GIST treatment requires understanding adaptation to KIT inhibition and apoptosis evasion.
• Addressing tumor evolution after successive treatments is key.
• Novel therapeutic strategies are needed to tackle GIST's oncogenic complexity while minimizing adverse events.